REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma

Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort

(2021) Liam G. Heaney et al.   CHEST

Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities

(2021) Thomas Casale et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study

(2021) Christian Domingo Ribas et al.   DRUGS

Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways

(2020) Didier Cataldo et al.   JOURNAL OF ASTHMA

Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma

(2020) Joanne E. Kavanagh et al.   CHEST

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme

(2020) Camille Taillé et al.   EUROPEAN RESPIRATORY JOURNAL

Real-world mepolizumab in the prospective severe asthma REALITI-A study – initial analysis

(2020) Tim Harrison et al.   EUROPEAN RESPIRATORY JOURNAL

Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data

(2020) Andreas Renner et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

(2020) Giorgio Walter Canonica et al.   World Allergy Organization Journal

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer

(2020) Bassel Nazha et al.   Future Oncology

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma

(2020) Jared Silver et al.   Journal of Asthma and Allergy

Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management

(2019) Eugene R Bleecker et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma

(2019) Barak Pertzov et al.   JOURNAL OF ASTHMA

One year of mepolizumab. Efficacy and safety in real-life in Italy

(2019) Diego Bagnasco et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Eosinophilic and Noneosinophilic Asthma

(2018) Tara F. Carr et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mepolizumab in the treatment of severe eosinophilic asthma

(2018) Ronald A. Strauss et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Oral corticosteroid exposure and adverse effects in asthmatic patients

(2018) Patrick W. Sullivan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease

(2018) Hiam Abdala-Valencia et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Consequences of long-term OCS therapy and its side effects in severe asthma in adults – A focused review of the impact data in the literature

(2018) Timm Volmer et al.   EUROPEAN RESPIRATORY JOURNAL

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study

(2018) Corrado Pelaia et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Randomised controlled trials in severe asthma: selection by phenotype or stereotype

(2018) Thomas Brown et al.   EUROPEAN RESPIRATORY JOURNAL

The Severe Asthma Network in Italy: Findings and Perspectives

(2018) Enrico Heffler et al.   Journal of Allergy and Clinical Immunology-In Practice

Biomarkers for severe eosinophilic asthma

(2017) Steven W. Yancey et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

(2017) Geoffrey L Chupp et al.   Lancet Respiratory Medicine

Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

(2015) Dominick E. Shaw et al.   EUROPEAN RESPIRATORY JOURNAL

Acute and chronic systemic corticosteroid–related complications in patients with severe asthma

(2015) Patrick Lefebvre et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

(2014) S. O'Neill et al.   THORAX

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET